De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Kontafarma China Holdings Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Feifei Wang

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Here's Why Kontafarma China Holdings Limited's (HKG:1312) CEO Compensation Is The Least Of Shareholders Concerns

May 31

Recent updates

Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?

Sep 04

Here's Why Kontafarma China Holdings Limited's (HKG:1312) CEO Compensation Is The Least Of Shareholders Concerns

May 31

There's No Escaping Kontafarma China Holdings Limited's (HKG:1312) Muted Revenues Despite A 61% Share Price Rise

May 24

Health Check: How Prudently Does Tongfang Kontafarma Holdings (HKG:1312) Use Debt?

Sep 15

Tongfang Kontafarma Holdings (HKG:1312) Has Debt But No Earnings; Should You Worry?

Apr 20

Is Tongfang Kontafarma Holdings (HKG:1312) A Risky Investment?

Nov 04

Tongfang Kontafarma Holdings' (HKG:1312) Shareholders Are Down 90% On Their Shares

Feb 18

These 4 Measures Indicate That Tongfang Kontafarma Holdings (HKG:1312) Is Using Debt Extensively

Dec 07

CEO

Feifei Wang

less than a year

Tenure

Mr. Feifei Wang is Executive Chairman & President of Kontafarma China Holdings Limited from June 7, 2024.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Feifei Wang	Executive Chairman & President	less than a year	geen gegevens	geen gegevens
Zixiu Guo	Financial Controller & Executive Director	less than a year	geen gegevens	geen gegevens
Jie Zhang	Chief Operating Officer	4.1yrs	geen gegevens	geen gegevens
Linna Qiao	VP & Executive Director	less than a year	geen gegevens	geen gegevens
Jiankun Liu	Executive Director	less than a year	geen gegevens	geen gegevens
Lok Tung Chan	Company Secretary	less than a year	geen gegevens	geen gegevens

0.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van 1312 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Feifei Wang	Executive Chairman & President	less than a year	geen gegevens	geen gegevens
Zixiu Guo	Financial Controller & Executive Director	less than a year	geen gegevens	geen gegevens
Linna Qiao	VP & Executive Director	less than a year	geen gegevens	geen gegevens
Jiankun Liu	Executive Director	less than a year	geen gegevens	geen gegevens
Lai Wah Tang	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens
Yu Huang	Non-Executive Director	10.6yrs	HK$1.67m	geen gegevens
Ho Ming Ho	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens
Xiaomin Yao	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens

0.3yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 1312 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.3 jaar), wat duidt op een nieuw bestuur.

Kontafarma China Holdings Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Kontafarma China Holdings Limited Announces Board Changes, with Effect from 1 September 2024

Kontafarma China Holdings Limited Announces CEO Changes

Here's Why Kontafarma China Holdings Limited's (HKG:1312) CEO Compensation Is The Least Of Shareholders Concerns

Kontafarma China Holdings Limited Announces Management Changes, Effect from 19 April 2024

Kontafarma China Holdings Limited, Annual General Meeting, Jun 07, 2024

Less than half of directors are independent

Recent updates

First half 2024 earnings released: EPS: HK$0.001 (vs HK$0.007 in 1H 2023)

Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?

Kontafarma China Holdings Limited Announces Board Changes, with Effect from 1 September 2024

Kontafarma China Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

Kontafarma China Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

New major risk - Share price stability

Kontafarma China Holdings Limited Announces CEO Changes

Here's Why Kontafarma China Holdings Limited's (HKG:1312) CEO Compensation Is The Least Of Shareholders Concerns

There's No Escaping Kontafarma China Holdings Limited's (HKG:1312) Muted Revenues Despite A 61% Share Price Rise

New minor risk - Share price stability

Kontafarma China Holdings Limited Announces Management Changes, Effect from 19 April 2024

Full year 2023 earnings released: HK$0.005 loss per share (vs HK$0.015 loss in FY 2022)

Kontafarma China Holdings Limited, Annual General Meeting, Jun 07, 2024

Kontafarma China Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Health Check: How Prudently Does Kontafarma China Holdings (HKG:1312) Use Debt?

First half 2023 earnings released: EPS: HK$0.007 (vs HK$0.009 loss in 1H 2022)

Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?

Kontafarma China Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

New major risk - Share price stability

Kontafarma China Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Full year 2022 earnings released: HK$0.015 loss per share (vs HK$0.003 loss in FY 2021)

Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?

Less than half of directors are independent

Health Check: How Prudently Does Tongfang Kontafarma Holdings (HKG:1312) Use Debt?

First half 2022 earnings released: HK$0.011 loss per share (vs HK$0.014 loss in 1H 2021)

Tongfang Kontafarma Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Tongfang Kontafarma Holdings Limited to Report First Half, 2022 Results on Aug 29, 2022

Less than half of directors are independent

Tongfang Kontafarma Holdings (HKG:1312) Has Debt But No Earnings; Should You Worry?

Tongfang Kontafarma Holdings Limited Announces Management Changes

Full year 2021 earnings released: HK$0.003 loss per share (vs HK$0.008 loss in FY 2020)

Is Tongfang Kontafarma Holdings (HKG:1312) A Risky Investment?

Executive Director Bingzhang Wei has left the company

Less than half of directors are independent

Tongfang Kontafarma Holdings Limited Provides Earnings Guidance for the Full Year of Fiscal 2020

Tongfang Kontafarma Holdings Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Tongfang Kontafarma Holdings' (HKG:1312) Shareholders Are Down 90% On Their Shares

These 4 Measures Indicate That Tongfang Kontafarma Holdings (HKG:1312) Is Using Debt Extensively

Minyi Holdings Limited entered into an agreement to acquire Real Jade Limited from Tongfang Kontafarma Holdings Limited (SEHK:1312) for approximately HKD 350 million.

First half earnings released

First half earnings released

Tongfang Kontafarma Holdings Limited to Report First Half, 2020 Results on Aug 28, 2020

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd